Production (Stage)
Monopar Therapeutics Inc.
MNPR
$37.11
-$0.905-2.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.58M | 1.15M | 590.60K | 657.80K | 757.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.22M | 11.07M | 1.57M | 1.79M | 1.72M |
| Operating Income | -3.22M | -11.07M | -1.57M | -1.79M | -1.72M |
| Income Before Tax | -2.63M | -10.93M | -1.30M | -1.72M | -1.64M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.63M | -10.93M | -1.30M | -1.72M | -1.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.63M | -10.93M | -1.30M | -1.72M | -1.64M |
| EBIT | -3.22M | -11.07M | -1.57M | -1.79M | -1.72M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.38 | -2.23 | -0.37 | -0.49 | -0.51 |
| Normalized Basic EPS | -0.23 | -1.39 | -0.23 | -0.31 | -0.32 |
| EPS Diluted | -0.38 | -2.23 | -0.37 | -0.49 | -0.51 |
| Normalized Diluted EPS | -0.23 | -1.39 | -0.23 | -0.31 | -0.32 |
| Average Basic Shares Outstanding | 6.99M | 4.90M | 3.52M | 3.50M | 3.20M |
| Average Diluted Shares Outstanding | 6.99M | 4.90M | 3.52M | 3.50M | 3.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |